As the CEO of Chicago-based Paragon Biosciences, Jeffrey Aronin has worked diligently to earn his recognition from Insights Care Magazine as an innovative leader in bioscience. Jeffrey has worked to bring life-altering drugs to patients in need by helping Paragon Biosciences become the industry lead, ushering in over 32 Novel and New Drug Approvals earned by the research and development teams. Paragon Biosciences, LLC works to build innovative biotechnology companies that are able to meet the sever and unique needs of patients, granting access to better healthcare with the help of other industry leaders.
Jeffrey Aronin has worked passionately to meet the needs of patients living with severe conditions. After finding Paragon Biosciences and making significant strides in the medical industry, Insights care honored the work of the firm by describing them as a “pioneer in venture innovation [that] invests in and incubates high-growth biotechnology companies”. Over the past couple of years, Paragon has made investments totaling over $450 million in pharmaceutical compounds. They have also built high-growth biopharmaceutical companies with the goal of treating those in need.
The success of Paragon Biosciences has been attributed to Jeffrey’s key leadership principles, which include his ability to recruit and maintain a team that intentionally works toward a common vision. For the past 15 years, Jeffrey has managed to maintain the same team with a common goal in mind. This goal is the improvement of the medical industry as well as the constant prioritization of the patients in need. For years, there have been a list of needs that have not been addressed by large pharmaceutical firms. Historically, this has been due to the complications of getting through the FDA approval process necessary to administer the medication. Through Paragon, Jeffrey Aronin has come up with a process that focuses on putting the patient first in the treatment and medication process.